VanEck Video Gaming and eSports ETF vs Immunovant Inc. Common Stock — how do they compare? VanEck Video Gaming and eSports ETF trades at $99.75 (market cap $248.06M), while Immunovant Inc. Common Stock trades at $30.34 (market cap $6.25B). The key difference: Immunovant Inc. Common Stock is far larger — about 25.2× VanEck Video Gaming and eSports ETF's market cap, and VanEck Video Gaming and eSports ETF is more actively traded (13,622 versus 1,755,411). Which is the better fit depends on your goals — on Pluang, investors hold VanEck Video Gaming and eSports ETF for 65 Days and Immunovant Inc. Common Stock for 0 Days on average.
| ESPO | IMVT | |
|---|---|---|
Market Cap | $248.06M | $6.25B |
Volume | 13,622 | 1,755,411 |
Sector | Sector/Thematic | Health |
52-Week High | $118.68 | $44.96 |
52-Week Low | $85.25 | $17.03 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | — | $5.35B |
Signals from Pluang's Aura AI — not financial advice
ESPO trades at $97.32, down 0.33% on the day, with a bullish technical signal from moving averages and neutral oscillators. Key support is at $97 and resistance at $98. Financial ratios are unavailable in the provided data, limiting fundamental insight. No recent news is available to drive sentiment.
The outlook is mixed: technicals suggest upward momentum, but the absence of fundamental data and recent news creates uncertainty. Risks include market volatility and lack of visibility on financial health. Investors need updated earnings and guidance for a clearer investment case.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →